Now showing items 1-8 of 8

    • Compositions and methods related to toll-like receptor-3 

      Kao, Cheng C.; Tharachaparamba, Ranjith Kumar (United States. Patent and Trademark OfficeTexas A&M University. Libraries, 2011-11-29)
      The invention relates to compositions and methods related to Toll-like receptor (TLR) polypeptides. In some embodiments, the invention relates to managing TLR3 related diseases. In further embodiments, the invention relates ...
    • Interferon dosage form and method therefor 

      Cummins, Joseph M. (United States. Patent and Trademark OfficeTexas A&M University. Libraries, 2002-04-16)
      Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of ...
    • Low dosage of interferon to enhance vaccine efficiency 

      Cummins, Joseph M. (United States. Patent and Trademark OfficeTexas A&M University. Libraries, 1989-04-11)
      A biologically active interferon can be administered to an animal in conjunction with the administration of a vaccine to improve the vaccine efficiency and allow the use of a smaller vaccination dose. This procedure will ...
    • Low-dose oral administration of interferons 

      Cummins, Joseph M. (United States. Patent and Trademark OfficeTexas A&M University. Libraries, 1999-06-08)
      Improved methods for administering an interferon (IFN) to a warm-blooded vertebrate are described. The methods employ oral administration of the IFN to the vertebrate in very low dosages, for example, 0.1 to 1.5 IU per ...
    • Treatment of autoimmune disorders with oral interferon 

      Cummins, Joseph M. (United States. Patent and Trademark OfficeTexas A&M University. Libraries, 1998-12-08)
      Autoimmune disorders are treated by the administration of human interferon, particularly IFN-α or IFN-β, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's ...
    • Treatment of hyperallergenic response with oral interferon 

      Cummins, Joseph M. (United States. Patent and Trademark OfficeTexas A&M University. Libraries, 1999-03-16)
      Hyperallergenic conditions are treated by the administration of interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. ...
    • Treatment of immuno-resistant disease with low-dose interferon 

      Cummins Jr., Joseph M. (United States. Patent and Trademark OfficeTexas A&M University. Libraries, 1991-05-28)
      Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of ...
    • Treatment of neoplastic disease with oral interferon 

      Cummins, Joseph M. (United States. Patent and Trademark OfficeTexas A&M University. Libraries, 1998-10-20)
      Neoplastic diseases are treated by the administration of human interferon, particularly IFN-α, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and ...